Bank of Montreal Can Grows Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)

Bank of Montreal Can raised its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) by 3.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 455,880 shares of the biopharmaceutical company’s stock after buying an additional 15,567 shares during the quarter. Bank of Montreal Can owned approximately 0.24% of Arbutus Biopharma worth $1,491,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of ABUS. Vanguard Group Inc. increased its holdings in shares of Arbutus Biopharma by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 8,980,864 shares of the biopharmaceutical company’s stock worth $29,367,000 after buying an additional 62,282 shares during the last quarter. State Street Corp raised its holdings in shares of Arbutus Biopharma by 50.2% in the 3rd quarter. State Street Corp now owns 4,407,133 shares of the biopharmaceutical company’s stock worth $16,967,000 after purchasing an additional 1,472,652 shares during the period. Geode Capital Management LLC lifted its position in Arbutus Biopharma by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 3,482,136 shares of the biopharmaceutical company’s stock valued at $11,390,000 after buying an additional 33,536 shares in the last quarter. Rangeley Capital LLC acquired a new position in shares of Arbutus Biopharma during the fourth quarter worth about $4,771,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Arbutus Biopharma by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,222,201 shares of the biopharmaceutical company’s stock worth $3,997,000 after acquiring an additional 9,955 shares in the last quarter. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Arbutus Biopharma Stock Performance

Shares of NASDAQ:ABUS opened at $3.15 on Friday. The stock has a market capitalization of $603.16 million, a price-to-earnings ratio of -7.33 and a beta of 1.45. Arbutus Biopharma Co. has a 1-year low of $2.63 and a 1-year high of $4.73. The company’s fifty day moving average is $3.29 and its two-hundred day moving average is $3.47.

Arbutus Biopharma (NASDAQ:ABUS) last posted its quarterly earnings data on Thursday, March 27th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $1.57 million during the quarter, compared to analysts’ expectations of $2.20 million. Arbutus Biopharma had a negative net margin of 1,137.65% and a negative return on equity of 68.18%. Sell-side analysts expect that Arbutus Biopharma Co. will post -0.39 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on ABUS. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Arbutus Biopharma in a research report on Tuesday, January 21st. StockNews.com raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, March 29th. Finally, Chardan Capital reissued a “buy” rating and set a $5.00 price objective on shares of Arbutus Biopharma in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Arbutus Biopharma currently has an average rating of “Moderate Buy” and a consensus price target of $5.50.

About Arbutus Biopharma

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.